ElevateBio’s $150 Million in Series A Financing Round

Goodwin advised ElevateBio on the round

ElevateBio, a Cambridge-based biotechnology holding company, executed operations to create and build a broad portfolio of cell and gene therapy companies through partnerships with leading academic researchers, medical centers and entrepreneurs.

ElevateBio’s fully integrated business model is structured to efficiently build single- and multi-product cell and gene therapy companies by providing scientific founders with centralized bench-to-bedside capabilities including world-class scientists, manufacturing facilities, drug development and commercialization expertise.

ElevateBio’s BaseCamp is a single R&D, process development and cGMP manufacturing company that provides centralized expertise for all ElevateBio portfolio companies, and also serves selected strategic partners. The company has closed $150 million in Series A financing co-led by the UBS Oncology Impact Fund managed by MPM Capital and F2 Ventures, joined by EcoR1 Capital, Redmile Group, and Samsara BioCapital.

The Goodwin team was led by partners Danielle Lauzon (Picture) and Mitchell Bloom, and associates Patricia Mets, Gabriela Morales-Rivera, Kimberly Maruncic and Katherine Hand, with tax assistance from partner Dan Karelitz.

Involved fees earner: Mitchell Bloom – Goodwin Procter; Katherine Hand – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Danielle Lauzon – Goodwin Procter; Kimberley Maruncic – Goodwin Procter; Patricia Mets – Goodwin Procter; Gabriela Morales-Rivera – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: ElevateBio, LLC;


Author: Ambrogio Visconti